MedTrace Logo

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

NCT03645824 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2022-08-22

No results posted yet for this study

Summary

The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD), thereby improving the outcome of SCT.

Conditions

Interventions

DRUG

Pacritinib

Patients receive up to 4 cycles of pacritinib before allo-SCT

Sponsors & Collaborators

  • Dutch Cancer Society

    collaborator OTHER

  • CTI BioPharma

    collaborator INDUSTRY

  • Stichting Hemato-Oncologie voor Volwassenen Nederland

    lead OTHER

Principal Investigators

  • Peter AW te Boekhorst, M.D. PhD · Erasmus Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-04
Primary Completion
2023-07-31
Completion
2027-02-28

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03645824 on ClinicalTrials.gov